# Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

> **NCT00332696** · PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 64 (actual)

## Conditions studied

- Peritoneal Neoplasms
- Intestinal Obstruction
- Carcinomatosis

## Interventions

- **DRUG:** Octreotide LAR
- **DRUG:** Octreotide (Immediate release)
- **DRUG:** methylprednisolone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00332696
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2008-09
- **Final completion:** 2008-09
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2011-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00332696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00332696, "Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00332696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*